Protein Kinase Inhibitors: all 15,278 studies that test it

Page 107 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Low-dose Dasatinib as First-line Treatment for Chronic Myeloid LeukemiaStatus unknownNCT03216070Phase 4
• X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With CrizotinibActive, not recruitingNCT03215693Phase 2
• A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat CancerCompletedNCT03215511Phase 1
• AZD1390 Administration of a Microdose [11C]AZD1390 to Healthy VolunteersCompletedNCT03215381Phase 1
• Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)Status unknownNCT03213587Phase 2
• Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer PatientsStatus unknownNCT03210064Phase 2
• Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)SuspendedNCT03208296Phase 1/2
• Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast CancerCompletedNCT03207529Phase 1
• iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)WithdrawnNCT03207334Phase 2
• Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 TrialsTerminatedNCT03207256Phase 2
• Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell LymphomasWithdrawnNCT03205891Phase 1
• Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML PatientsStatus unknownNCT03205267Phase 2
• A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLCActive, not recruitingNCT03202940Phase 1/2
• Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in HumansTerminatedNCT03201952Phase 1
• Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLCStatus unknownNCT03201146Phase 1/2
• Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)CompletedNCT03200587Phase 1
• A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid CancerStatus unknownNCT03199677Phase 2
• A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)CompletedNCT03198949Phase 2
• A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell MalignanciesCompletedNCT03198650Phase 1
• Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03194685Phase 1
• Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric AdenocarcinomaCompletedNCT03193918Phase 1
• Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal CancerWithdrawnNCT03193814Phase 2
• Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT03193424Phase 2
• KISS Study: Kinase Inhibition With Sprycel Start upActive, not recruitingNCT03193281Phase 2
• Apatinib in Refractory Colorectal CancerCompletedNCT03190616Phase 2
• Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer PatientsWithdrawnNCT03190239Phase 2
• A Phase I Study of ICP-022 in Healthy SubjectsCompletedNCT03189017Phase 1
• First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and LymphomasCompletedNCT03188965Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian ParticipantsCompletedNCT03188783Phase 1
• Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDSCompletedNCT03187288Phase 1
• Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125CompletedNCT03185195Phase 1
• Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male VolunteersCompletedNCT03184168Phase 1
• Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBCCompletedNCT03184090Phase 2
• The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid TumorsTerminatedNCT03182673Phase 1
• The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) TrialStatus unknownNCT03182634Phase 2
• Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid TumorsTerminatedNCT03182257Phase 1
• Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal CarcinomaCompletedNCT03180476Phase 2
• Impact of Ribociclib on Head and Neck Squamous Cell CancerTerminatedNCT03179956Early Phase 1
• A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03178552Phase 2/3
• Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate CancerCompletedNCT03177460Phase 1
• Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid TumorsCompletedNCT03175497Phase 1
• Open-label Study on Treatment of Primary Aldosteronism With EverolimusCompletedNCT03174171Phase 2
• A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and SimvastatinCompletedNCT03174041Phase 1
• The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid LeukemiaStatus unknownNCT03173612Not applicable
• Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell CarcinomaActive, not recruitingNCT03172754Phase 1/2
• POETIG Trial - POnatinib After rEsisTance to Imatinib in GISTStatus unknownNCT03171389Phase 2
• Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03170960Phase 1
• Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITDCompletedNCT03170895Phase 2
• Apatinib Treatment for Advanced Esophagus CancerStatus unknownNCT03170310Phase 2
• Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung CancerCompletedNCT03170206Phase 1
• Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric CancerCompletedNCT03170180Phase 2
• Phase II Study of Single Agent LenvatinibStatus unknownNCT03168074Phase 2
• Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid CarcinomaStatus unknownNCT03167385Phase 2
• Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard ChemotherapyWithdrawnNCT03166904Phase 2
• Phase Ib Study of Chiauranib in Patients With Ovarian CancerCompletedNCT03166891Phase 1/2
• Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard ChemotherapyWithdrawnNCT03166176Phase 2
• A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia MyelofibrosisActive, not recruitingNCT03165734Phase 3
• APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLCWithdrawnNCT03164694Phase 2
• A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03164057Phase 2
• Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.Status unknownNCT03163381Phase 2
• Selumetinib and Olaparib in Solid TumorsActive, not recruitingNCT03162627Phase 1
• A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
• Immunomodulatory Effects of Rapamycin on Pregnancy Rate of Patient With Recurrent Implantation FailureCompletedNCT03161340Phase 2
• A Study of HMPL-453 in Patients With Advanced Solid MalignanciesStatus unknownNCT03160833Phase 1/2
• Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)TerminatedNCT03159936Early Phase 1
• NCT Neuro Master Match - N²M² (NOA-20)CompletedNCT03158389Phase 1/2
• A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)CompletedNCT03158103Phase 1
• Bone Metastasis on the Survival of Gefitinib Effective PatientsCompletedNCT03157310Not applicable
• A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung CancerCompletedNCT03155009Phase 2
• Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR MutationStatus unknownNCT03153358Phase 2
• Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)Active, not recruitingNCT03153202Phase 1/2
• Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationStatus unknownNCT03151161Phase 2
• Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease TrialActive, not recruitingNCT03150914Phase 3
• QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid TumorsWithdrawnNCT03147976Phase 2
• Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaActive, not recruitingNCT03147612Phase 2
• Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract CancersStatus unknownNCT03144856Phase 2
• Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.Status unknownNCT03144843Phase 2
• An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other MalignanciesTerminatedNCT03144661Phase 1
• Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple MyelomaCompletedNCT03143985Phase 1
• Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous SclerosisCompletedNCT03140449Phase 3
• A Study To Evaluate ASN002 In Subjects With Atopic DermatitisCompletedNCT03139981Phase 1
• UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib AloneSuspendedNCT03139747Phase 2
• PAZIT Study for Children and Young Adults With Relapsed or Refractory SarcomaCompletedNCT03139331Phase 1
• Effect of Probenecid on Pexidartinib PharmacokineticsCompletedNCT03138759Phase 1
• OMO-1 in Solid MalignanciesTerminatedNCT03138083Phase 1/2
• A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719CompletedNCT03138070Not applicable
• A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.CompletedNCT03137134Phase 1
• Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCCCompletedNCT03136627Phase 1/2
• Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line ChemotherapyStatus unknownNCT03135977Phase 2
• A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult ParticipantsCompletedNCT03135106Phase 1
• Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITDStatus unknownNCT03135054Phase 2
• A Study of SY-1365 in Adult Patients With Advanced Solid TumorsTerminatedNCT03134638Phase 1
• Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory LeukemiaActive, not recruitingNCT03132454Phase 1
• Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN LossCompletedNCT03131908Phase 1/2
• Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC.Status unknownNCT03130881Phase 1
• Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)CompletedNCT03130790Phase 2/3
• Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain AmyloidosisWithdrawnNCT03130348Phase 2
• Maintenance Treatment of Apatinib in Nasopharyngeal CarcinomaStatus unknownNCT03130270Phase 2
• Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2CompletedNCT03129828Phase 1/2
• The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung CancerStatus unknownNCT03129698Phase 2

← Protein Kinase Inhibitors overview